The Role of Ablative Radiotherapy to Liver Oligometastases from Colorectal Cancer

AbstractPurpose of ReviewThis review describes recent data supporting locoregional ablative radiation in the treatment of oligometastatic colorectal cancer liver metastases.Recent FindingsStereotactic body radiotherapy (SBRT) demonstrates high rates of local control in colorectal cancer liver metastases when a biologically equivalent dose of  >  100 Gy is delivered. Future innovations to improve the efficacy of SBRT include MRI-guided radiotherapy (MRgRT) to enhance target accuracy, systemic immune activation to treat extrahepatic disease, and genomic customization. Selective internal radiotherapy (SIRT) with y-90 is an intra-arterial t herapy that delivers high doses to liver metastases internally which has shown to increase liver disease control in phase 3 trials. Advancements in transarterial radioembolization (TARE) dosimetry could improve local control and decrease toxicity.SummarySBRT and SIRT are both promising options in treating unresectable metastatic colorectal cancer liver metastases. Identification of oligometastatic patients who receive long-term disease control from either therapy is essential. Future advancements focusing on improving radiation design and customization could further improve efficacy and toxicity.
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research